Evrysdi® (risdiplam) - Drug Discovery of the Year Prize Lecture 2022
Dr Lutz Mueller presents the Drug Discovery of the Year 2022 Prize Lecture. In December 2021, Evrysdi® (risdiplam) was awarded Drug Discovery of the Year 2022: https://www.bps.ac.uk/news-events/new... Risdiplam is a first-in-class oral small-molecule mRNA splicing modifier and a life-saving medicine for patients with spinal muscular atrophy (SMA). More information on the Drug Discovery of the Year award: https://www.bps.ac.uk/membership-awar... ---------- Recorded at Pharmacology 2022 on Wednesday 14 September 2022 ---------- Speaker: Dr Lutz Mueller, Roche, Switzerland
▶︎
Metformin as an Anti-Aging Drug with Dr. Nir Barzilai
▶︎
How AI Cracked the Protein Folding Code and Won a Nobel Prize
▶︎
The Future of Global Education: Jobs, Skills & Survival of Universities
▶︎
The Touch-Brain Axis & the Premature Baby - Professor Francis McGlone
▶︎
Session Day 2 - Genetics & Innovation
▶︎
An Update on Spinal Muscular Atrophy Current Treatment Paradigms and Ongoing Research
▶︎
KN3: Targeting the Blood-Brain Barrier: New Frontiers in Neurodegeneration and Brain Health
▶︎
Cure SMA's Community Webinar on the FDA Approval of Evrysdi risdiplam
▶︎
Video #241 - The REALITY of Spinraza and Evrysdi
▶︎
Ed Wild research updates | Huntington's disease
▶︎
Eric Topol on the Future of Healthy Aging
▶︎
Learning how to learn | Barbara Oakley | TEDxOaklandUniversity
▶︎
Session Day 1 - Welcome & Innovations in PF Treatment
▶︎
Axia ASD - "Autism and Alcohol" Matt Tinsley - PDSG Febrary 2020
▶︎
By Design: Behe, Lennox, and Meyer on the Evidence for a Creator
▶︎
How Proctor’s texts in Karen Read lawsuit could free dangerous criminals
▶︎
Multimodal Treatment
▶︎
Immune Biomarkers for CMV Infection
▶︎
How Spinraza (nusinersen) and Evrysdi treat Spinal Muscular Atrophy (SMA) through splice-switching
▶︎